Literature DB >> 8307460

Expression of mutant p53 protein in hepatocellular carcinoma.

J D Collier1, M Carpenter, A D Burt, M F Bassendine.   

Abstract

p53 mutations are a common genetic finding in hepatocellular carcinoma from areas of high aflatoxin exposure. Recent small studies have shown that p53 gene mutations may be less common in areas with a low prevalence of hepatocellular carcinoma such as Great Britain. The protein product of mutant p53 can be detected immunohistochemically because of its longer half life in comparison with native protein. This study used a novel monoclonal antibody DO-7, raised against recombinant p53 and effective in routinely processed biopsy specimen tissue, to detect the mutant protein in a series of 45 cases of hepatocellular carcinoma occurring in white subjects resident in the United Kingdom. Focal nuclear labelling was seen in four cases (9%); surrounding cirrhotic tissue in one of these was negative for p53 expression. This study shows that p53 mutations are a rare event in hepatocarcinogenesis in Great Britain, an area of low aflatoxin exposure, and supports the concept of geographical variations in the cause and pathogenesis of hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8307460      PMCID: PMC1374641          DOI: 10.1136/gut.35.1.98

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  31 in total

1.  T antigen is bound to a host protein in SV40-transformed cells.

Authors:  D P Lane; L V Crawford
Journal:  Nature       Date:  1979-03-15       Impact factor: 49.962

2.  Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation.

Authors:  P Hinds; C Finlay; A J Levine
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

3.  Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life.

Authors:  C A Finlay; P W Hinds; T H Tan; D Eliyahu; M Oren; A J Levine
Journal:  Mol Cell Biol       Date:  1988-02       Impact factor: 4.272

4.  Base substitution mutations induced by metabolically activated aflatoxin B1.

Authors:  P L Foster; E Eisenstadt; J H Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1983-05       Impact factor: 11.205

5.  Growth regulation of a cellular tumour antigen, p53, in nontransformed cells.

Authors:  N C Reich; A J Levine
Journal:  Nature       Date:  1984 Mar 8-14       Impact factor: 49.962

6.  Microinjection of monoclonal antibody to protein p53 inhibits serum-induced DNA synthesis in 3T3 cells.

Authors:  W E Mercer; D Nelson; A B DeLeo; L J Old; R Baserga
Journal:  Proc Natl Acad Sci U S A       Date:  1982-10       Impact factor: 11.205

7.  Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies.

Authors:  J Bártek; J Bártková; B Vojtĕsek; Z Stasková; J Lukás; A Rejthar; J Kovarík; C A Midgley; J V Gannon; D P Lane
Journal:  Oncogene       Date:  1991-09       Impact factor: 9.867

8.  An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53.

Authors:  B Vojtĕsek; J Bártek; C A Midgley; D P Lane
Journal:  J Immunol Methods       Date:  1992-07-06       Impact factor: 2.303

9.  p53 Mutations in human hepatocellular carcinomas from Germany.

Authors:  S Kress; U R Jahn; A Buchmann; P Bannasch; M Schwarz
Journal:  Cancer Res       Date:  1992-06-01       Impact factor: 12.701

10.  Mutation pattern of the p53 gene as a diagnostic marker for multiple hepatocellular carcinoma.

Authors:  T Oda; H Tsuda; A Scarpa; M Sakamoto; S Hirohashi
Journal:  Cancer Res       Date:  1992-07-01       Impact factor: 12.701

View more
  5 in total

1.  Alpha-fetoprotein and p53 autoantibodies in patients with chronic hepatitis C.

Authors:  J Raedle; W K Roth; G Oremek; W F Caspary; S Zeuzem
Journal:  Dig Dis Sci       Date:  1995-12       Impact factor: 3.199

2.  p53 expression in hepatocellular carcinoma in a population in Singapore with endemic hepatitis B virus infection.

Authors:  A Wee; M Teh; G C Raju
Journal:  J Clin Pathol       Date:  1995-03       Impact factor: 3.411

3.  Is p53 gene mutation an indicatior of the biological behaviors of recurrence of hepatocellular carcinoma?

Authors:  I-Shyan Sheen; Kuo-Shyang Jeng; Ju-Yann Wu
Journal:  World J Gastroenterol       Date:  2003-06       Impact factor: 5.742

4.  Hepatocellular carcinomas with a high proliferation index and a low degree of apoptosis and necrosis are associated with a shortened survival.

Authors:  Y Soini; N Virkajärvi; V P Lehto; P Pääkkö
Journal:  Br J Cancer       Date:  1996-05       Impact factor: 7.640

5.  Prognostic value of tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy.

Authors:  Bernhard Robl; Chantal Pauli; Sander Martijn Botter; Beata Bode-Lesniewska; Bruno Fuchs
Journal:  BMC Cancer       Date:  2015-05-09       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.